311
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
INDUSTRY SPONSORED SYMPOSIA
pageSunday, June 1, 2014 13:15 - 15:15Auditorium Fresenius Medical Care 312Elicium 2 Amgen 313 Elicium 1 Gambro 314Forum Otsuka Pharmaceuticals Europe 315E104-107 Vifor Fresenius Medical Care Renal Pharma 316G106-107 Keryx Biopharmaceuticals 317G104-105 AbbVie 318G102-103 B.Braun 319
18:45 - 19:45G102-103 Alexion Pharma International 320
Monday, June 2, 2014 06:45 - 07:45 G104-105 AbbVie 321
13:15 - 15:15Auditorium Fresenius Medical Care Renal Pharma 322Elicium 2 Baxter 323Elicium 1 Sanofi 324E104-107 Novartis 325G106-107 Asahi Kasei Medical 326G104-105 Pharmacosmos 327G102-103 ZS Pharmaceuticals 328Emerald Chiesi Farmaceutici 329
312
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Sunday, June 1, 2014 13:15 - 15:15Auditorium
Unravelling Vascular Calcification Processes in Search of Advanced Therapeutic Avenues for CKD Patients
Chairs: Bernard Canaud, Bad Homburg, Germany Andreas Pasch, Basel, Switzerland
Pathogenesis of Vascular Calcification: Phosphate or calciprotein particles - who is the cul-prit?Makoto Kuro-O, Yakushiji Shimotsuke, Japan
Ascertaining the Vascular Calcification Risk: The Role of Non-Invasive Imaging Techniques Paolo Raggi, Alberta, Canada
Reducing the Vascular Calcification and Cardiovascular Burden in Renal Replacement The-rapy: Potential of Convective Treatment ModalitiesJeroen Kooman, Maastricht, The Netherlands
Concluding RemarksAndrea Pasch, Basel, Switzerland
Organised by FRESENIUS MEDICAL CARE
313
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Sunday, June 1, 2014 13:15 - 15:15Elicium 2
Management of CKD-MBD and renal anaemia: new considerations in 2014
Chair: Charles A. Herzog, Minneapolis, USA
Cardiovascular risk in CKD-MBD: The Cardiologist’s perspectiveCharles A. Herzog, Minneapolis, USA
The Nephrologist’s perspectiveDavid C. Wheeler, London, UK
Recent changes in anaemia management practice patterns: Where are we heading? Francesco Locatelli, Lecco, Italy
Organised by AMGEN
314
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Sunday, June 1, 2014 13:15 - 15:15Elicium 1
Individualization of HD therapy - the way to address clinical challenges
Chair: Claudio Ronco, Vicenza, Italy
Who benefits from HDF and why, based on recent clinical trials?Paul Cockwell, Birmingham, UK
How to prevent intradialytic hypotension while reducing volume overload?Rajiv Agarwal, Indianapolis, USA
Dialysis standard of care for high-bleeding-risk HD patients - what the HepZero study tells usMaurice Laville, Lyon, France
Organised by GAMBRO
315
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Sunday, June 1, 2014 13:15 - 15:15Forum
Current and future management strategies in a changing ADPKD landscape
Chair: Albert Ong, Sheffield, UK
Introduction - Evolution and new insights into the management of ADPKDAlbert Ong, Sheffield, UK
Clinical perspectivenes on assessing the natural progression of the diseaseBertrand Knebelman, Paris, France
Current clinical management and new and emerging treatment optionsAndreas Serra, Zurich, Switzerland
Summary - A changing paradigm - what can we hope to achieve?Albert Ong, Sheffield, UK
Organised by oTSUKA PHARMACEUTICALS EURoPE
316
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Sunday, June 1, 2014 13:15 - 15:15E104-107
Exploring Controversies in Iron Therapy - Looking Beyond Treating Anaemia
Chair: Carlo Gaillard, Groningen, The Netherlands
Welcome and IntroductionCarlo Gaillard, Groningen, The Netherlands
Controversies in Diagnosis and Treatment of Iron Deficiency in Patients With CKDIain Macdougall, London, UK
Targeting Higher Serum Ferritin With Intravenous Ferric Carboxymaltose in Patients With ND-CKD Not Receiving ESA - The FIND-CKD StudySimon Roger, Gosford, Australia
Benefits of Treating Iron Deficiency in Patients With or Without AnaemiaAdriaan Voors, Groningen, The Netherlands
Panel DiscussionCarlo Gaillard, Groningen, The Netherlands
Organised by VIFoR FRESENIUS MEDICAL CARE RENAL PHARMA
317
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Sunday, June 1, 2014 13:15 - 15:15G106-107
A New Frontier in CKD Anemia Understanding: the interlinking roles of Inflammation, FGF-23, and Oral Iron
Chairs: David Goldsmith, London, UK Christoph Wanner, Würzburg, Germany
A Silent Killer - The Role of IV Iron in Inflammation in Kidney DiseasePeter Stenvinkel, Stockholm, Sweden
Emerging CKD Clinical Markers - a Discussion of FGF-23 and IronMyles S. Wolf, Chicago, USA
The role of Oral Iron in the Optimization of Anaemia Management in CKDSteve Fishbane, New York, USA
Panel Discussion
Organised by KERYx BIoPHARMACEUTICALS
318
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Sunday, June 1, 2014 13:15 - 15:15G104-105
Optimal Therapy of SHPT: Is it Possible?
Chairs: Marc Vervloet, Amsterdam, The Netherlands Armando L. Negri, Buenos Aires, Argentina
Lessons learned from VITAL, IMPACT and PRIMODaniel Coyne, St. Louis, USA
Measuring PTH: How SHPT treatment is affected by the assay used and type of PTH measured Berthold Hocher, Potsdam, Germany
When VitD treatment fails; what is next?Mario Cozzolino, Milan, Italy
Question and answer
Organised by ABBVIE
319
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Sunday, June 1, 2014 13:15 - 15:15G102-103
Dialysis treatment: Status and factors to improve
Chair: Jürgen Floege, Aachen, Germany
Treatment reality in 2014 in Europe - are we on the right track? Results from the DOPPS. Friedrich K. Port, Ann Arbor, USA
How to optimize dialysis therapy in times of cost reduction? Andrew Davenport, London, UK
HDF as a future therapy? Johannes Mann, Munich, Germany
Organised by B.BRAUN
320
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Sunday, June 1, 2014 18:45 - 19:45G102-103
Diagnostic challenges in identifying causes of TMA
Chair: Dirk Kuypers, Leuven, Belgium
Welcome and introduction to TMADirk Kuypers, Leuven, Belgium
Differential diagnosis of TMA: a case based reviewJosep M. Campistol, Barcelona, Spain
Management of aHUS in 2014Christophe Legendre, Paris, France
ConclusionQuestions and answers
Organised by ALExIoN PHARMA INTERNATIoNAL
321
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Monday, June 2, 2014 06:45 - 07:45G104-105
A Tale of Two Nephropathies: The AKI-CKD Paradox
Chair: Dick de Zeeuw, Groningen, The Netherlands
Welcome and introduction
The two faces of GFR decline: When is a decrease in eGFR beneficial?Hiddo Lambers Heerspink, Groningen, The Netherlands
Ongoing research in the prevention and management of AKIAndrew Lewington, Leeds, UK
Ongoing research in the prevention and management of CKDDick de Zeeuw, Groningen, The Netherlands
Question and answer
Organised by ABBVIE
322
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Monday, June 2, 2014 13:15 - 15:15Auditorium
Why does the world need another phosphate binder?
Chairs: Mariano Rodriguez, Cordoba, Spain Mario Cozzolino, Milano, Italy
Phosphate and nutrition in the dialysis patient - reasons to interveneDenis Fouque, Lyon, France
The importance of adherence in drug treatment for a CKD patientAdrian Covic, Iasi, Romania
New options for phosphate control achieved with a minimum of pillsMarkus Ketteler, Coburg, Germany
Organised by FRESENIUS MEDICAL CARE RENAL PHARMA
323
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Monday, June 2, 2014 13:15 - 15:15Elicium 2
Bringing the Benefits of High Dose Haemodialysis to the Home with a Novel Haemodialysis System
Chair: Pieter ter Wee, Amsterdam, The Netherlands
Dialysis Inadequacy – Understanding the Limitations of Conventional HaemodialysisChristopher McIntyre, Nottingham, UK
Improving Clinical Endpoints and Health-Related Quality of Life with High Dose Haemo-dialysisTom Cornelis, Maastricht, The Netherlands
Overcoming Barriers to the Growth of Home Haemodialysis through Device InnovationBruce Culleton, Chicago, USA
Organised by BAxTER
324
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Monday, June 2, 2014 13:15 - 15:15Elicium 1
Healthy Kidneys, Bones, and Heart: The Cardio-Endocrine-Renal Connection, and Risk Reduction in the CKD-MBD Patient
Chair: Michel Jadoul, Brussels, Belgium
Calcium Homeostasis - A Delicate Balance; A Cardiologist’s PerspectiveKlaus Witte, Leeds, UK
The Endocrinology Perspective on Calcium Use in Healthy Men and Women, and in those with CKDSophie Jamal, Toronto, Canada
Incorporating Phosphorus and Calcium Management Strategies into the Care of Patient with CKDGrahame Elder, Sidney, Australia
Organised by SANOFI
325
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Monday, June 2, 2014 13:15 - 15:15E104-107
Reshaping Patient Outcomes: from Science to Clinical Practice in the Management of Tube-rous Sclerosis Complex (TSC) - Associated Renal Angiomyolipoma (AML)
Chair: Bernard A. Zonnenberg, Utrecht, The Netherlands
Reshaping patient outcomes: the importance of early accurate diagnosis and adherence to guidelinesBernard A. Zonnenberg, Utrecht, The Netherlands
Bridging the gap: understanding the mTOR signaling pathway and developing targeted therapyJulian Sampson, Cardiff, UK
Optimizing long term management of adult patients with renal angiomyolipoma and TSCJ. Chris Kingswood, Brighton, UK
Organised by NOVARTIS
326
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Monday, June 2, 2014 13:15 - 15:15G106-107
Oxidative Stress as an Emerging Risk Factor in Haemodialysis. How to Manage?
Chairs: Francesco Locatelli, Lecco, Italy Peter Stenvinkel, Stockholm, Sweden
Inflammation and oxidative stress in ESRD - partners in crimePeter Stenvinkel, Stockholm, Sweden
Antioxidant and pro-oxidant imbalance in uraemic milieuJean-Paul Cristol, Montpellier, France
Clinical studies of Vitamin E bonded polysulfone dialysis membranesSimon Lines, Norwich, UK
Discussion and closing remarksFrancesco Locatelli, Lecco, Italy
Organised by ASAHI KASEI MEDICAL
327
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Monday, June 2, 2014 13:15 - 15:15G104-105
New comparative clinical data on intravenous iron in CKD patients
Chair: Andrzej Wiecek, Katowice, Poland
New data: Are IV-iron preparations toxic to the patients?Gunnar Heine, Homburg, Germany
New randomised comparative efficacy study data between intravenous iron compounds, iso-maltoside 1000 and iron sucrose in CKD patients on dialysisSunil Bhandari, Hull, UK
High dose intravenous iron efficacy and safety with IV Iron isomaltoside 1000 in pre-dialysis CKD patientsPhilip Kalra, Salford, UK
Organised by PHARMACoSMoS
328
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Monday, June 2, 2014 13:15 - 15:15G102-103
Hyperkalemia: Old Foe with New Faces
Chair: Peter A. McCullough, Dallas, USA
Current Epidemiology of HyperkalemiaCsaba P. Kovesdy, Memphis, USA
Hyperkalemia and Cardiorenal DisordersPeter A. McCullough, Dallas, USA
Standard and Emerging TreatmentDavid Goldsmith, London, UK
Supported by ZS PHARMACEUTICALS
329
InduS
try Sp
onSo
red S
yMpo
SIa
w w w . e r a e d t a 2 0 1 4 . o r g
Industry Sponsored Symposia
Monday, June 2, 2014 13:15 - 15:15Emerald
The new frontier of Immunosuppression: the fast, stable, round-the-clock graft protection
Chair: Teun Van Gelder, Rotterdam, The Netherlands
IntroductionTeun Van Gelder, Rotterdam, The Netherlands
Tailoring pharmacokinetics for kidney transplant patientsPierre Marquet, Limoges, France
Improving immunosuppressive treatments: from clinical trials to clinical practiceJosep M. Grinyó, Barcelona, Spain
Discussion and summaryTeun Van Gelder, Rotterdam, The Netherlands
Organised by CHIESI FARMACEUTICI
Top Related